Xenetic Biosciences Inc
NASDAQ:XBIO
Xenetic Biosciences Inc
Revenue
Xenetic Biosciences Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Xenetic Biosciences Inc
NASDAQ:XBIO
|
Revenue
$2.5m
|
CAGR 3-Years
79%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
45%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$29.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
19%
|
See Also
What is Xenetic Biosciences Inc's Revenue?
Revenue
2.5m
USD
Based on the financial report for Dec 31, 2023, Xenetic Biosciences Inc's Revenue amounts to 2.5m USD.
What is Xenetic Biosciences Inc's Revenue growth rate?
Revenue CAGR 10Y
45%
Over the last year, the Revenue growth was 49%. The average annual Revenue growth rates for Xenetic Biosciences Inc have been 79% over the past three years , and 45% over the past ten years .